Migraine - Drug Pipeline Landscape, 2023
Migraine is a neurological disorder that is associated with recurrent headaches. The headache is characterized by affecting one side of the head, pulsating, moderate to severe in intensity which last for few hours to three days.
The underlying cause of migraine is unknown. It is believed that, migraine may be due to a mixture of environmental triggers and genetical factors. Change in hormonal levels during puberty may also affect the cause of migraine. Triggering factors include fatigue, certain foods, alcohol, and whether. Psychological stress quoted to be a risk factor.
The symptoms of migraine is presented one or two days before the attack, which is presented as constipation, mood changes, fatigue, fluid retention, frequent yawning, and increased urination. Few people experience migraine aura, including visual phenomena, vision loss, pins and needles sensation in arm and legs, weakness or numbness in the face and difficulty speaking. Symptoms during migraine attack includes pain on one of the head, pain throbbing or pulsing, sensitivity to light, sound, smell and touch, and also experience nausea and vomiting.
The migraine diagnosis is based on medical history, symptoms, physical and neurological examination, Neuroimaging tests are used to find other causes of headaches which includes MRI and CT scans.
The treatment plan of migraines includes the combination of lifestyle adjustments, OTC pain or migraine medications like NSAIDs, triptans, dihydroergotamine, CGRP antagonists, opioid medications, anti-nausea drugs, alternative care includes meditation, acupressure or acupuncture.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Migraine treatment such as Zavegepant, AXS-07, STS101, and others. Key players involved in the development of therapies to treat Migraine are Eli Lilly and Co, AbbVie, Biohaven Pharmaceuticals and others. Four drugs are under late-stage Pre-Registration Stage, 7 drugs are in Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. Biohaven Ltd is expecting zavegepant nasal spray with a Prescription Drug Fee Act (PDUFA) goal date set for the Q1 2023. In Nov 2022, Satsuma Pharmaceuticals announced top-line results of SUMMIT Phase III trial of STS101.
Global Insight Service's, Migraine - Drug Pipeline Landscape, 2023 report provides an overview of the Migraine pipeline drugs. This report covers detailed insights on Migraine drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Migraine pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook